Lotus Bio-Technology Development

Lotus Bio-Technology Development Equity

The The Equity of Lotus Bio-Technology Development (LBTD) as of Oct 20, 2026 is -80,900.00 USD. In the previous year, The Equity was -45,200.00 USD — a change of 78.98% (lower).

Equity

-80,900.00USD

YoY

78.98%

Last updated:

In 2017, Lotus Bio-Technology Development's equity was -80,900.00 USD, a 78.98% increase from the -45,200.00 USD equity in the previous year.

The Lotus Bio-Technology Development Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2014
-26,500.00 USD
Jan 1, 2015
-45,200.00 USD
Jan 1, 2016
-45,200.00 USD
Jan 1, 2017
-80,900.00 USD
The Lotus Bio-Technology Development Equity history
YEAREquityYoY
-80,900.00USD+78.98%
-45,200.00USD0.00%
-45,200.00USD+70.57%
-26,500.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Lotus Bio-Technology Development Stock analysis

What does Lotus Bio-Technology Development do? Lotus Bio-Technology Development Corp, listed in 2013, operates in Hong Kong and specializes in refining organic materials to produce natural consumer products. The company is exploring opportunities in organic farming and growth in China, focusing on organizational planning and business development. Currently in the start-up phase with no revenue generated, it is developing its business plan and website. Lotus Bio-Technology Development is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Lotus Bio-Technology Development's Equity

Lotus Bio-Technology Development's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Lotus Bio-Technology Development's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Lotus Bio-Technology Development's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Lotus Bio-Technology Development's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Lotus Bio-Technology Development’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Lotus Bio-Technology Development stock

The Equity of Lotus Bio-Technology Development is -80,900.00 USD in 2017.

The Equity of Lotus Bio-Technology Development changed from -45,200.00 USD to -80,900.00 USD, representing a 78.98% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Lotus Bio-Technology Development since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Lotus Bio-Technology Development historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Lotus Bio-Technology Development

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Lotus Bio-Technology Development